All In Biotech

Drug Trial Radar · NCT06534892

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

A Phase 3b, Randomized, Open Label, Multicountry, Multi-center, Extension and Crossover Vaccination Study to Evaluate the Immunogenicity and Safety of Different Revaccination Schedules and Persistence of a Single Dose of the RSVPreF3 OA Vaccine in Adults Aged 60 Years and Above Who Participated in the RSV OA=ADJ-006 Study

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 10,212 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

10,212

Actual

Start

Aug 1, 2024

Primary completion

Sep 30, 2026

Study completion Sep 30, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vaccine, * To give the opportunity to participants who received only placebo in the RSVOA=ADJ- 006 study, to receive a dose of the RSVPreF3 OA vaccine and collect additional safety information.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • RSVPreF3 OA vaccineBiological

    RSVPreF3 OA vaccine administered at different timepoints (revaccination groups) or for the first time (crossover group)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RSV-A neutralizing titers expressed as Geometric mean titers (GMTs) in RSV_PreS4 group at Day 1Time frame: At Day 1
  2. RSV-A neutralizing titers expressed as GMTs in RSV_PreS4 group at Day 31Time frame: At Day 31
  3. RSV-B neutralizing titers expressed as GMTs in RSV_PreS4 group at Day 1Time frame: At Day 1
  4. RSV-B neutralizing titers expressed as GMTs in RSV_PreS4 group at Day 31Time frame: At Day 31
  5. RSV-A neutralizing titers expressed as Mean geometric increase (MGI) in RSV_PreS4 groupTime frame: From Day 1 to Day 31
  6. RSV-B neutralizing titers expressed as MGI in RSV_PreS4 groupTime frame: From Day 1 to Day 31
  7. Percentage of participants with RSV-A neutralizing titers greater than or equal to (>=) cut-off in RSV_PreS4 group at Day 1Time frame: At Day 1
  8. Percentage of participants with RSV-A neutralizing titers >= cut-off in RSV_PreS4 group at Day 31Time frame: At Day 31
  9. Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS4 group at Day 1Time frame: At Day 1
  10. Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS4 group at Day 31Time frame: At Day 31
  11. Percentage of participants with seroresponse rate (SRR) for RSV-A neutralizing titers in RSV_PreS4 groupTime frame: At Day 31
  12. Percentage of participants with SRR for RSV-B neutralizing titers in RSV_PreS4 groupTime frame: At Day 31
  13. RSV-A neutralizing titers expressed as GMT in RSV_PreS5 group at Day 1Time frame: At Day 1
  14. RSV-A neutralizing titers expressed as GMT in RSV_PreS5 group at Month 12Time frame: At Month 12
  15. RSV-A neutralizing titers expressed as GMT in RSV_PreS5 group at Month 13Time frame: At Month 13
  16. RSV-A neutralizing titers expressed as GMT in RSV_PreS5 group at Month 24Time frame: At Month 24
  17. RSV-B neutralizing titers expressed as GMTs in RSV_PreS5 group at Day 1Time frame: At Day 1
  18. RSV-B neutralizing titers expressed as GMTs in RSV_PreS5 group at Month 12Time frame: At Month 12
  19. RSV-B neutralizing titers expressed as GMTs in RSV_PreS5 group at Month 13Time frame: At Month 13
  20. RSV-B neutralizing titers expressed as GMTs in RSV_PreS5 group at Month 24Time frame: At Month 24
  21. RSV-A neutralizing titers expressed as MGI in RSV_PreS5 group from Month 12 to Month 13Time frame: From Month 12 to Month 13
  22. RSV-A neutralizing titers expressed as MGI in RSV_PreS5 group from Month 12 to Month 24Time frame: From Month 12 to Month 24
  23. RSV-B neutralizing titers expressed as MGI in RSV_PreS5 group from Month 12 to Month 13Time frame: From Month 12 to Month 13
  24. RSV-B neutralizing titers expressed as MGI in RSV_PreS5 group from Month 12 to Month 24Time frame: From Month 12 to Month 24
  25. Percentage of participants with RSV-A neutralizing titers >=cut-off in RSV_PreS5 group at Day 1Time frame: At Day 1
  26. Percentage of participants with RSV-A neutralizing titers >=cut-off in RSV_PreS5 group at Month 12Time frame: At Month 12
  27. Percentage of participants with RSV-A neutralizing titers >=cut-off in RSV_PreS5 group at Month 13Time frame: At Month 13
  28. Percentage of participants with RSV-A neutralizing titers >=cut-off in RSV_PreS5 group at Month 24Time frame: At Month 24
  29. Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS5 group at Day 1Time frame: At Day 1
  30. Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS5 group at Month 12Time frame: At Month 12
  31. Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS5 group at Month 13Time frame: At Month 13
  32. Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS5 group at Month 24Time frame: At Month 24
  33. Percentage of participants with seroresponse rate (SRR) for RSV-A neutralizing titers in RSV_PreS5 groupTime frame: At Month 13
  34. Percentage of participants with SRR for RSV-B neutralizing titers in RSV_PreS5 groupTime frame: At Month 13

Locations

251 sites in 17 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Huntsville, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Cerritos, California

  • GSK Investigational Site

    Doral, Florida

  • GSK Investigational Site

    Fort Myers, Florida

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    Lake City, Florida

  • GSK Investigational Site

    Melbourne, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Pinellas Park, Florida

  • GSK Investigational Site

    The Villages, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Savannah, Georgia

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Evansville, Indiana

  • GSK Investigational Site

    Mishawaka, Indiana

  • GSK Investigational Site

    El Dorado, Kansas

  • GSK Investigational Site

    Newton, Kansas

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    Rockville, Maryland

  • GSK Investigational Site

    Richfield, Minnesota

  • GSK Investigational Site

    Kansas City, Missouri

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Rochester, New York

  • GSK Investigational Site

    Hickory, North Carolina

  • GSK Investigational Site

    Mooresville, North Carolina

  • GSK Investigational Site

    Rocky Mount, North Carolina

  • GSK Investigational Site

    Salisbury, North Carolina

  • GSK Investigational Site

    Winston-Salem, North Carolina

  • GSK Investigational Site

    Centerville, Ohio

Showing 40 of 251 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.